Observation On The Efficacy Of Gifitinib Treating Advanced Non-small Cell Lung Cancer Harboring EGFR Mutation

Objective:(1)This study is designated to analyze clinical characteristics of advanced non-small cell lung cancer Patients with EGFR sensitive mutations,and to observe the efficacy of EGFR tyrosine kinase inhibitors.(2)This study is undertaken to analysis efficacy of Gefitinib in advanced non-small-cell lung cancer Patients harboring EGFR deletion mutation in exon 19 and the L858 R Point mutation in exon21.(3)This study is undertaken to analysis the efficacy of Gefitinib as the first-line and second-line treatment in advanced non-small cell lung cancer Patients with EGFR mutations.Methods:70 Patients with advanced non-small-cell lung cancer harboring EGFR activating mutations(deletion mutation in exon 19 and the L858 R Point mutation in exon21),taking Gefitinib as first or second line treatment were collected from January 2013 to December2014 in tumor hos Pital in Shanxi Province.Among all the cases collected,46 Patients harbor exon 19 deletion and 24 Patients harbor exon 21 L858 R mutation;36 Patients take Gefitinib as the first-line treatment and 34 Patients take Gefitinib as the second-line treatment.The main end Point is median Progression-free survival(PFS),the second end Point is objective res Ponse rate(ORR)?disease control rate(DCR).Results:The Log-rank analysis and Cox multi Ple factors analysis showed that age,gender,TNM stage,PS score did not relate to the Progression-free survival.The total ORR was 64.3%,median PFS was 8.81 months [95%CI7.87-9.73] and the Patients harboring EGFR exon 19 deletion had similar median PFS(8.88 months Venus 8.67 months, P=0.96)?similar ORR(69.6% versus 54.2%, X20.05/2=1.63, P=0.20),and similar DCR(84.8% versus 91.7%, X20.05/2=0.19, P=0.66) with Patients harboring EGFR L858 R Point mutation.As to the first-line and second-line treatments we did not find significant difference in PFS(9.22 months vs 8.37 months,P=0.507)?ORR(63.89%vs 58.82%,?20.05/2=1.46,P=0.23)?DCR(88.9% vs 88.24%,?20.05/2=0.06,P=0.94).Conclusion:Age,gender,TNM stage,PS score did not relate to the Progression-free survival.Gefitinib has no significant differences in efficacy between Patients with EGFR exon 19 deletion and Patients with EGFR L858 R Point mutation and the first-line and second-line treatments.